Clinical efficacy and safety of a water‐soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas. (27th November 2012)

• Record Type: Journal Article
• Authors: Rivera, P.; Åkerlund‐Denneberg, N.; Bergvall, K.; Kessler, M.; Rowe, A.; Willmann, M.; Persson, G.; Kastengren Fröberg, G.; Westberg, S.; von, H.
• Is Part Of: Journal of small animal practice. Volume 54:Number 1(2013:Jan.)
• Page Start: 20
• Page End: 27
• Publication Date: 2012-11-27
• Subjects: Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; 636.089
• DOI: 10.1111/j.1748-5827.2012.01304.x
• Languages: English
• ISSNs: 0022-4510

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jsap1304-sec-0001" sec-type="section"> <title>Objective</title> <p> <bold>To determine the clinical efficacy and safety of a cremophor‐free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours.</bold> </p> </sec> <sec id="jsap1304-sec-0018" sec-type="section"> <title>Methods</title> <p> <bold>Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m<sup>2</sup>intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression‐free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events.</bold> </p> </sec> <sec id="jsap1304-sec-0002" sec-type="section"> <title>Results</title> <p> <bold>Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression.</bold> </p> </sec> <sec id="jsap1304-sec-0003" sec-type="section"> <title>Clinical Significance</title> <p> <bold>Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.</bold> </p> </sec> </abstract>